Insights into adeno-associated virus-based ocular gene therapy: A bibliometric and visual analysis

Background: Adeno-associated virus (AAV) plays a vital role in ocular gene therapy and has been widely studied since 1996. This study summarizes and explores the publication outputs and future research trends of AAV-based ocular gene therapy. Methods: Publications and data about AAV-based ocular gene therapy were downloaded from the Web of Science Core Collection or ClinicalTrials.gov database. The publications and data were analyzed by Microsoft Excel, CiteSpace, VOS viewer, and a free online platform (http://bibliometric.com). Results: Totally 832 publications from the Web of Science Core Collection relevant to AAV-based ocular gene therapy were published from 1996 to 2022. These publications were contributed by research institutes from 42 countries or regions. The US contributed the most publications among these countries or regions, notably the University of Florida. Hauswirth WW was the most productive author. “Efficacy” and “safety” are the main focus areas for future research according to the references and keywords analysis. Eighty clinical trials examined AAV-based ocular gene therapy were registered on ClinicalTrials.Gov. Institutes from the US and European did the dominant number or the large proportion of the trials. Conclusions: The research focus of the AAV-based ocular gene therapy has transitioned from the study in biological theory to clinical trialing. The AAV-based gene therapy is not limited to inherited retinal diseases but various ocular diseases.

[1]  Wenjin Zou,et al.  Global trends and prospects in research of artificial cornea over past 20 years: a bibliometric and visualized analysis , 2022, International Ophthalmology.

[2]  Xiaonan Sheng,et al.  Research trends in the field of retinitis pigmentosa from 2002 to 2021: a 20 years bibliometric analysis , 2022, International Ophthalmology.

[3]  Honghai Zhou,et al.  Hotspots and trends in multiple myeloma bone diseases: A bibliometric visualization analysis , 2022, Frontiers in Pharmacology.

[4]  Qianchuan Zhao,et al.  Immunotherapy improves disease prognosis by affecting the tumor microenvironment: A bibliometric study , 2022, Frontiers in Immunology.

[5]  Yan Li,et al.  Research status, hotspots and trends of acupuncture and moxibustion in the treatment of Alzheimer’s disease: A bibliometric analysis , 2022, Medicine.

[6]  Tianxin Lin,et al.  Global research trends and foci of artificial intelligence-based tumor pathology: a scientometric study , 2022, Journal of Translational Medicine.

[7]  T. Ciulla,et al.  Advancements in ocular gene therapy delivery: vectors and subretinal, intravitreal, and suprachoroidal techniques , 2022, Expert opinion on biological therapy.

[8]  Weihua Yang,et al.  Systematic Bibliometric and Visualized Analysis of Research Hotspots and Trends on the Application of Artificial Intelligence in Ophthalmic Disease Diagnosis , 2022, Frontiers in Pharmacology.

[9]  D. Cacchiarelli,et al.  Therapeutic homology-independent targeted integration in retina and liver , 2022, Nature Communications.

[10]  J. Ciolino,et al.  Bibliometric and visualized analysis of ocular drug delivery from 2001 to 2020. , 2022, Journal of controlled release : official journal of the Controlled Release Society.

[11]  Yuquan Wei,et al.  Delivery of nVEGFi using AAV8 for the treatment of neovascular age-related macular degeneration , 2022, Molecular therapy. Methods & clinical development.

[12]  A. Ljubimov,et al.  Gene therapy in the anterior eye segment. , 2021, Current gene therapy.

[13]  Yin Zhao,et al.  Ad- and AAV8-mediated ABCA1 gene therapy in a murine model with retinal ischemia/reperfusion injuries , 2021, Molecular therapy. Methods & clinical development.

[14]  P. Sieving,et al.  Host Immune Responses after Suprachoroidal Delivery of AAV8 in Nonhuman Primate Eyes , 2020, bioRxiv.

[15]  J. Wijnholds,et al.  Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays , 2020, International journal of molecular sciences.

[16]  U. Schraermeyer,et al.  A new rat model of treatment-naive quiescent choroidal neovascularization induced by human VEGF165 overexpression , 2020, Biology Open.

[17]  F. Mingozzi,et al.  AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  F. Behar-Cohen,et al.  Ocular gene therapies in clinical practice: viral vectors and nonviral alternatives. , 2019, Drug discovery today.

[19]  Min Song,et al.  Visualizing a field of research: A methodology of systematic scientometric reviews , 2019, PloS one.

[20]  T. Bek,et al.  Suppression of Choroidal Neovascularization by AAV-Based Dual-Acting Antiangiogenic Gene Therapy , 2019, Molecular therapy. Nucleic acids.

[21]  G. Gao,et al.  Adeno-associated virus vector as a platform for gene therapy delivery , 2019, Nature Reviews Drug Discovery.

[22]  N. Slater,et al.  Pharmaceutical Development of AAV-Based Gene Therapy Products for the Eye , 2018, Pharmaceutical Research.

[23]  P. Sieving,et al.  Trans-ocular Electric Current In Vivo Enhances AAV-Mediated Retinal Gene Transduction after Intravitreal Vector Administration , 2018, Molecular therapy. Methods & clinical development.

[24]  R. MacLaren,et al.  AAV2/8 Anti-angiogenic Gene Therapy Using Single-Chain Antibodies Inhibits Murine Choroidal Neovascularization , 2018, Molecular therapy. Methods & clinical development.

[25]  Pallavi Sharma,et al.  Preclinical Evaluation of ADVM-022, a Novel Gene Therapy Approach to Treating Wet Age-Related Macular Degeneration , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[26]  Vetle I. Torvik,et al.  Self-citation is the hallmark of productive authors, of any gender , 2018, PloS one.

[27]  Keerang Park,et al.  Transduction Patterns of Adeno-associated Viral Vectors in a Laser-Induced Choroidal Neovascularization Mouse Model , 2018, Molecular therapy. Methods & clinical development.

[28]  Michel Sadelain,et al.  Gene therapy comes of age , 2018, Science.

[29]  Zheng He,et al.  AAV-mediated gene delivery of the calreticulin anti-angiogenic domain inhibits ocular neovascularization , 2018, Angiogenesis.

[30]  Kathleen A. Marshall,et al.  Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial , 2017, The Lancet.

[31]  Feng Zhang,et al.  Genome editing abrogates angiogenesis in vivo , 2017, Nature Communications.

[32]  A. Lewin,et al.  Delivery of CR2-fH Using AAV Vector Therapy as Treatment Strategy in the Mouse Model of Choroidal Neovascularization , 2017, Molecular therapy. Methods & clinical development.

[33]  H. Khanna,et al.  Advances in Gene Therapy for Diseases of the Eye , 2016, Human gene therapy.

[34]  I. Constable,et al.  Gene Therapy for Age-Related Macular Degeneration , 2016, Asia-Pacific journal of ophthalmology.

[35]  A. Auricchio,et al.  Vector platforms for gene therapy of inherited retinopathies , 2014, Progress in Retinal and Eye Research.

[36]  Meen Chul Kim,et al.  Emerging trends and new developments in regenerative medicine: a scientometric update (2000 – 2014) , 2014, Expert opinion on biological therapy.

[37]  Deniz Dalkara,et al.  In Vivo–Directed Evolution of a New Adeno-Associated Virus for Therapeutic Outer Retinal Gene Delivery from the Vitreous , 2013, Science Translational Medicine.

[38]  William J Feuer,et al.  Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. , 2012, Archives of ophthalmology.

[39]  W. Hauswirth,et al.  Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. , 2008, Human gene therapy.

[40]  Edwin M Stone,et al.  Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics , 2008, Proceedings of the National Academy of Sciences.

[41]  Nick Tyler,et al.  Effect of gene therapy on visual function in Leber's congenital amaurosis. , 2008, The New England journal of medicine.

[42]  Kathleen A. Marshall,et al.  Safety and efficacy of gene transfer for Leber's congenital amaurosis. , 2008, The New England journal of medicine.

[43]  A. Tessitore,et al.  AAV-mediated gene transfer for retinal diseases , 2006, Expert opinion on biological therapy.

[44]  Julianne Cheek,et al.  What's in a Number? Issues in Providing Evidence of Impact and Quality of Research(ers) , 2006, Qualitative health research.

[45]  W. Hauswirth,et al.  Gene therapy restores vision-dependent behavior as well as retinal structure and function in a mouse model of RPE65 Leber congenital amaurosis. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[46]  Charles Auffray,et al.  F1000Prime recommendation of An index to quantify an individual's scientific research output. , 2005 .

[47]  W. Hauswirth,et al.  Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[48]  Jorge E. Hirsch,et al.  An index to quantify an individual’s scientific research output that takes into account the effect of multiple coauthorship , 2009, Scientometrics.

[49]  I. Constable,et al.  Quantitative model demonstrating that recombinant adeno‐associated virus and green fluorescent protein are non‐toxic to the rat retina , 2003, Clinical & experimental ophthalmology.

[50]  J. Bennett,et al.  Gene therapy and retinitis pigmentosa: advances and future challenges , 2001, BioEssays : news and reviews in molecular, cellular and developmental biology.

[51]  Jean Bennett,et al.  Gene therapy restores vision in a canine model of childhood blindness , 2001, Nature Genetics.

[52]  F. Liang,et al.  AAV-mediated delivery of ciliary neurotrophic factor prolongs photoreceptor survival in the rhodopsin knockout mouse. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[53]  J. Bennett,et al.  Real-time, noninvasive in vivo assessment of adeno-associated virus-mediated retinal transduction. , 1997, Investigative ophthalmology & visual science.

[54]  J. Grist,et al.  Rescue of photoreceptor function by AAV-mediated gene transfer in a mouse model of inherited retinal degeneration , 1997, Gene Therapy.

[55]  W. Hauswirth,et al.  Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[56]  W. Hauswirth,et al.  A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells , 1996, Journal of virology.

[57]  D. Hunt,et al.  Gene transfer into the mouse retina mediated by an adeno-associated viral vector. , 1996, Human molecular genetics.

[58]  J. Tratschin,et al.  A human parvovirus, adeno-associated virus, as a eucaryotic vector: transient expression and encapsidation of the procaryotic gene for chloramphenicol acetyltransferase , 1984, Molecular and cellular biology.

[59]  N. Muzyczka,et al.  Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[60]  B. Casto,et al.  Adenovirus-Associated Defective Virus Particles , 1965, Science.

[61]  Donald W. Pfaff,et al.  Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain , 1994, Nature Genetics.